×
About 240,925 results

FDA Approves Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma Following CR
https://www.onclive.com/view/fda-approves-adjuvant-pembrolizumab-for-stage-iib-or-iic-melanoma-following-cr

Dec 4th, 2021 - The FDA has approved pembrolizumab (Keytruda) for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection (CR). The regulatory agency also expanded the indication for the immunotherapy for adjuvant use in patients with stage III melanoma following CR to include pediatric patients aged 12 yers and older. The indication for the agent's ...

Darolutamide Plus Docetaxel/ADT Significantly Improves OS in Metastatic Hormone-Sensitive Prostate Cancer
https://www.onclive.com/view/darolutamide-plus-docetaxel-adt-significantly-improves-os-in-metastatic-hormone-sensitive-prostate-cancer

Dec 3rd, 2021 - The addition of darolutamide (Nubeqa) to docetaxel and androgen deprivation therapy (ADT) resulted in a significant improvement in overall survival (OS) compared with docetaxel/ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC), meeting the primary end point of the phase 3 ARASENS trial (NCT02799602).1 Detailed findings from the trial will be shared at an upcomin...

FDA Grants Priority Review to Luspatercept-aamt for Non–Transfusion Dependent Beta Thalassemia
https://www.onclive.com/view/fda-grants-priority-review-to-luspatercept-aamt-for-non-transfusion-dependent-beta-thalassemia

Dec 3rd, 2021 - The FDA has granted priority review to the supplemental biologics license application (sBLA) for luspatercept-aamt (Reblozyl) for the treatment of anemia in adults with non–transfusion dependent (NTD) β-thalassemia. The European Medicines Agency has also validated the Type II variation for the agent’s use in the same indication.1 The applications were supported by safety and efficacy data yiel...

Liso-cel Significantly Prolongs EFS Over SOC in Second-Line Relapsed/Refractory LBCL
https://www.onclive.com/view/liso-cel-significantly-prolongs-efs-over-soc-in-second-line-relapsed-refractory-lbcl

Dec 3rd, 2021 - Lisocabtagene maraleucel (Breyzani; liso-cel) significantly prolonged event-free survival (EFS) and progression-free survival and improved complete responses (CRs) compared with standard of care (SOC) when used in the second-line treatment of patients with relapsed or refractory large B-cell lymphoma (LBCL), according to data from a prespecified interim analysis of the phase 3 TRANSFORM trial (...

Hospitals refused to give patients ivermectin. Lockdowns and political pressure followed.
https://www.mdedge.com/infectiousdisease/article/249430/covid-19-updates/hospitals-refused-give-patients-ivermectin
Matt Volz, Kaiser Health News

Dec 3rd, 2021 - One Montana hospital went into lockdown and called police after a woman threatened violence because her relative was denied her request to be treated with ivermectin. Officials of another Montana hospital accused public officials of threatening and harassing their health care workers for refusing to treat a politically connected COVID-19 patient with that antiparasitic drug or hydroxychloroquin.

Omicron Creep Begins; Autism Cases Jump; States Ready Abortion Restrictions, Bans
https://www.medpagetoday.com/infectiousdisease/covid19/95989

Dec 3rd, 2021 - Note that some links may require registration or subscription. New York health officials have identified five cases of the Omicron coronavirus variant in Long Island, Queens, and Brooklyn. (Gothamist) Officials in Minnesota and Colorado announced the first cases of Omicron infection in their respective states. (Reuters, Denver Post) A confirmed Omicron case in Hawaii raised the number of affect...

Frontline Pembrolizumab Plus Chemotherapy Approved in Japan for Esophageal Carcinoma
https://www.onclive.com/view/frontline-pembrolizumab-plus-chemotherapy-approved-in-japan-for-esophageal-carcinoma

Dec 3rd, 2021 - The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has approved the PD-1 inhibitor pembrolizumab (Keytruda) for frontline use in combination with 5-fluorouracil (5-FU) plus cisplatin chemotherapy in patients with radically unresectable, advanced, or recurrent esophageal carcinoma, according to a news release from Merck, the manufacturer of pembrolizumab.1 The approval represents the f...

COVID-19 and the immunocompromised physician
https://www.mdedge.com/psychiatry/article/249407/covid-19-updates/covid-19-and-immunocompromised-physician
Tanya Thomas, MD

Dec 2nd, 2021 - Working feverishly to complete the myriad patient notes accumulated throughout a hectic day, my phone vibrated – alerting me to a number that, over the past several years, has wrought uncertainty, grief, and overwhelming relief. Answering hesitantly, I listened to my physician’s pharmacist inform me of unexpected and alarming news.

De-Escalated Approaches Continue to Show Benefit in HER2+ Breast Cancer
https://www.onclive.com/view/de-escalated-approaches-continue-to-show-benefit-in-her2-breast-cancer

Dec 2nd, 2021 - The shift away from chemotherapy as a standard treatment for patients with HER2-positive breast has continued with the incorporation of de-escalated therapies into the treatment paradigm, according to Deborah L. Toppmeyer, MD. Allowing patients to avoid potential adverse events associated with chemotherapy has been a key benefit of expanded treatment options, Toppmeyer said. She added that the...

AHN Cancer Institute Chair and Internationally Renowned Cancer Surgeon David L. Bartlett, MD, Opens Pittsburgh Office
https://www.onclive.com/view/ahn-cancer-institute-chair-and-internationally-renowned-cancer-surgeon-david-l-bartlett-md-opens-pittsburgh-office

Dec 2nd, 2021 - David L. Bartlett, MD, a renowned cancer researcher and clinician specializing in advanced surgical treatments for abdominal cancers, has reopened his Pittsburgh practice and will begin seeing patients at AHN Cancer Institute – Allegheny General on May 21. Appointments are now being accepted. Dr. Bartlett joined AHN in May 2020 as Chair of AHN Cancer Institute and began his AHN surgical practi...

Children with uncontrolled asthma at higher risk of being bullied
https://www.mdedge.com/pediatrics/article/249386/asthma/children-uncontrolled-asthma-higher-risk-being-bullied
Diana Swift

Dec 2nd, 2021 - The risk of bullying and teasing is higher in children and young people with poorer asthma control, an international study reported. Published online in the Archives of Disease in Childhood, the Room to Breathe survey of 943 children in six countries found 9.

Secura Bio Withdraws Panobinostat Plus Bortezomib/Dexamethasone Myeloma Indication in the United States
https://www.onclive.com/view/secura-bio-withdraws-panobinostat-plus-bortezomib-dexamethasone-myeloma-indication-in-the-united-states

Dec 2nd, 2021 - Secura Bio has decided to withdraw the approval of the new drug application for panobinostat (Farydak) for use in combination with bortezomib (Velcade) and dexamethasone to treat patients with multiple myeloma who have previously received at least 2 regimens, including bortezomib and an immunomodulatory agent.1 The combination regimen was granted an accelerated approval from the regulatory age...

Year in Review: Bipolar Disorder and Schizophrenia
https://www.medpagetoday.com/psychiatry/generalpsychiatry/95982

Dec 2nd, 2021 - The limits of psychiatry have been tested over 2021 amidst the mental health fallout of the COVID-19 pandemic. Grim reports have detailed the uptick in people struggling with mental health and higher COVID-related mortality rates among these individuals, especially for those with schizophrenia or bipolar disorder. But 2021 also saw key developments in therapeutic developments and treatment appr...

Cleveland Clinic Launches Trial Examining Preventive Vaccine for TNBC
https://www.onclive.com/view/cleveland-clinic-launches-trial-examining-preventive-vaccine-for-tnbc

Dec 2nd, 2021 - Cleveland Clinic has partnered with Anixa Biosciences, Inc. to open a phase 1 trial examining a vaccine aimed at preventing the development of triple-negative breast cancer (TNBC), according to a press release.1 The study will determine the maximum-tolerated dose of the vaccine in patients with early-stage TNBC, as well as characterize and optimize the body’s immune response to it. We are hop...

Perception vs Reality; Building a Decision Team; Active Surveillance Prevails
https://www.medpagetoday.com/hematologyoncology/othercancers/95971

Dec 2nd, 2021 - A pivotal clinical trial of the antibody-drug conjugate mirvetuximab soravtansine met the primary endpoint of objective response in previously treated ovarian cancer, ImmunoGen announced. An oncologist learns an important lesson about disconnect between perception and reality. (JCO Art of Oncology) An older breast cancer patient nearing end of life, who also happens to be a physician, makes dif...

Did Trump Have COVID at First Debate? Cats Busted for Misinfo; Myeloma Drug Yanked
https://www.medpagetoday.com/infectiousdisease/covid19/95968

Dec 2nd, 2021 - Note that some links may require registration or subscription. Donald Trump tested positive for COVID-19 days before the first presidential debate against Joe Biden, according to his chief of staff at the time and other former aids; Trump denounced the claims as "fake news." (Washington Post) In order to track travel-related Omicron cases, the CDC ordered airlines to share data on passengers ar...

U.S. to Tighten Testing for Travelers Amid Omicron Worries
https://www.nytimes.com/live/2021/11/30/world/omicron-variant-covid
The New York Times;

Dec 2nd, 2021 - The U.S. will require air travelers to provide a negative test within 24 hours of their departure. A judge blocked a vaccine mandate for U.S. health workers.

FDA Grants Breakthrough Device Designation to ZetaMet for Metastatic Bone Cancers
https://www.onclive.com/view/fda-grants-breakthrough-device-designation-to-zetamet-for-metastatic-bone-cancers

Dec 1st, 2021 - The FDA’s Centers for Devices and Radiological Health has granted a breakthrough device designation to ZetaMet technology for use in the treatment of metastatic bone cancers and osteologic interventions, according to an announcement from Zetagen Therapeutics.1 The synthetic, small-molecule, inductive biologic technology was designed to target and resolve metastatic bone lesions, as well as inh...

For older adults, smelling the roses may be more difficult
https://www.mdedge.com/internalmedicine/article/249337/covid-19-updates/older-adults-smelling-roses-may-be-more-difficult
Judith Graham; Kaiser Health News

Dec 1st, 2021 - The reports from COVID-19 patients are disconcerting. Only a few hours before, they were enjoying a cup of pungent coffee or the fragrance of flowers in a garden.

Treatment Sequencing Could Change With Complementary Combinations and CAR T Options in B-ALL
https://www.onclive.com/view/treatment-sequencing-could-change-with-complementary-combinations-and-car-t-options-in-b-all

Dec 1st, 2021 - Significant progress with rapidly evolving therapies, including blinatumomab (Blincyto), inotuzumab ozogamicin (Besponsa), and chimeric antigen receptor (CAR) T-cell therapy, has been made to extend the median overall survival (OS) and improve outcomes for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Antibody-based therapies and CAR T-cell therapies are not mut...